Drugs affected by AKT1
About AKT1
AKT1 sits in the signaling pathway downstream of dopamine receptors in the brain. A common variant near the gene (rs2494732) has been linked, in several observational studies, to a higher risk of psychotic symptoms in people who use cannabis. The effect is modest and not deterministic, but it's part of why cannabis affects some users very differently than others.[1]
C/C carriers appear to be at higher risk of cannabis-induced psychotic experiences than T/T carriers. The signal is most relevant for adolescents and heavy users.
What we test for AKT1
Gene2Rx uses definitions covering 2 named AKT1 alleles, built from 1 variant in Gene2Rx definitions. Results depend on the variants available in your upload.
- Named alleles
- 2
- Defined variants
- 1
- Source
- Gene2Rx definitions
- Genome build
- GRCh38
- Normal Function 1
- Risk Genotype 1
What do these allele names mean?
AKT1 alleles are named by the underlying DNA variant rather than a star number. For example, c.61C>T describes a single base change at position 61 of the coding sequence.
DNA variant labels identify sequence differences. Their interpretation depends on the particular gene, the evidence, and the variants that can be assessed in your data. A DNA result does not directly measure enzyme activity.
The source of these definitions is listed above. Missing variants or incomplete coverage can leave a result indeterminate.
Medications with AKT1 information
This list contains 1 medication with AKT1 information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
References
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Explore AKT1 in your report
Informational only, not medical advice. The presence of a AKT1 pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.